Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio

The article highlights three major healthcare transactions: Lilly licensed Hanmi’s sonefpeglutide with $75 million upfront and up to $1.185 billion in milestones, Servier agreed to buy Edgewise’s muscular dystrophy business for $1.55 billion upfront plus up to $1.1 billion in milestones, and Avenzo will go public via merger with Rallybio backed by a $215 million private financing. The deals underscore continued M&A and capital formation in rare disease and oncology, with Lilly gaining exclusive ex-Korea rights to a Phase II GLP-2 program and Servier securing sevasemten for Becker and Duchenne muscular dystrophy. Avenzo’s transaction should leave the combined company funded into late 2028 and trading under AVZO if closed in Q4 2026.

Analysis

This is a clean signal that big pharma is still paying up for de-risked, mechanism-differentiated assets in areas where reimbursement is less cyclical and competition is structurally thin. The common thread is not just rarity, but platform optionality: each deal buys a foothold in a therapeutic lane where follow-on indications, label expansion, or adjacent assets can compound value far beyond the headline program. That favors strategic buyers with balance-sheet firepower and hurts smaller biotechs whose standalone financing windows depend on showing clean mid-stage efficacy before the market fully rerates the story.

For EWTX, the takeout multiple is a tell that the market has been underpricing neuromuscular IP that can be translated into a broader franchise. The second-order effect is pressure on other orphan neuromuscular developers: once a large European commercial org validates the category, smaller peers lose some bargaining power in future partnership talks, and the market will start valuing platform breadth over single-asset optionality. The risk is binary timing: if pivotal data disappoint or regulatory language becomes ambiguous, the long-dated M&A premium can compress quickly, but that is more a months-to-years risk than a near-term trading problem.

Rallybio is the cleaner asymmetry. The merger effectively monetizes a weak public-market structure into a funded oncology vehicle, which should reduce distress discounting in the stock, but the deal also suggests investors are willing to finance clinical-stage oncology when the capitalization extends into the late 2020s. The hidden winner may be private biotech crossover funds that can now use this template to force similar recapitalizations elsewhere; the hidden loser is any small-cap oncology name still relying on serial dilution rather than partnering or consolidation.

Key Decisions for Investors

• Long EWTX into the closing window, but only as a merger-arb style position rather than a momentum trade; target 6-10% gross spread capture with hard risk control around any regulatory or financing noise before Q3 2026.
• Short a basket of underfunded small-cap neuromuscular/rare-disease names against a long EWTX or sector-ETF proxy; the deal raises the bar for standalone capital raises and should widen the gap between platform assets and single-asset stories over the next 3-6 months.
• Long RLYB on event-driven terms through Q4 2026 if the stock trades at a meaningful discount to implied post-merger financing value; upside is financing-overhang removal, while downside is mostly deal failure, making this a cleaner asymmetric catalyst trade.
• Consider a long basket of large-cap strategic acquirers with oncology/rare-disease M&A capacity versus short a basket of cash-burning development biotechs; the current environment rewards balance sheets and should persist for 2-4 quarters if rates stay stable.
• Do not chase Lilly on this announcement; treat it as confirmation of platform breadth, not a near-term earnings driver. The better expression is to own the likely next acquisition targets in GI/rare disease where Phase II data and strategic scarcity can still force a rerating.